InvestorsHub Logo
Followers 14
Posts 817
Boards Moderated 0
Alias Born 02/24/2010

Re: None

Saturday, 12/20/2014 11:20:49 AM

Saturday, December 20, 2014 11:20:49 AM

Post# of 403756
Brilacidin should be able to capture not only Daptomycin 1 billion annual market for ABSSSI but Vanomycin as well. One day treatment with a higher cure rate should be able to trump a generic. With a MOA of ripping off the plasma membrane of the bacteria, not ingested, broad usage of Brilacidin should be accepted because as the Borg 7 of 9 stated "resistance is futile".